Mycophenolate Dosing
For transplant recipients, start mycophenolate mofetil at 1 g twice daily (2 g/day total) for kidney transplants or 1.5 g twice daily (3 g/day total) for heart and liver transplants, administered on an empty stomach, with dose adjustments based on renal function, neutropenia, and gastrointestinal tolerance. 1, 2
Standard Dosing by Indication
Solid Organ Transplantation (Adults)
Kidney Transplant:
- Mycophenolate mofetil: 1 g orally twice daily (2 g/day total) 2
- Mycophenolic acid (enteric-coated): 720 mg twice daily 3
- Initiate as soon as possible post-transplant 2
Heart Transplant:
- Mycophenolate mofetil: 1.5 g orally twice daily (3 g/day total) 2
Liver Transplant:
- Mycophenolate mofetil: 1.5 g orally twice daily (3 g/day total) 2
Autoimmune Conditions (Adults)
Lupus Nephritis:
- Initial treatment (Class III/IV): Mycophenolate mofetil 3 g/day for 6 months 4
- Maintenance therapy: Reduce to 2 g/day after initial response 4
- Class V nephritis: 3 g/day for 6 months 4
Interstitial Lung Disease/Systemic Autoimmune Rheumatic Diseases:
- Starting dose: Mycophenolate mofetil 500 mg twice daily 3
- Therapeutic dose: Gradually increase to 1,000-1,500 mg twice daily 3
- Mycophenolic acid alternative: Start 360 mg twice daily, increase to 720-1,080 mg twice daily 3
Autoimmune Hepatitis:
- Starting dose: 1 g daily 5
- Maintenance dose: 1.5-2 g daily 5
- Range: 500 mg to 3 g daily based on tolerance 5
- Most effective for azathioprine intolerance (58% response) rather than refractory disease (23% response) 5
Pediatric Dosing (≥3 months old)
Kidney Transplant:
- 600 mg/m² twice daily (maximum 2 g/day) 2
- BSA 1.25-1.5 m²: May use 750 mg twice daily 2
- BSA >1.5 m²: May use 1 g twice daily 2
Heart/Liver Transplant:
Critical Dose Adjustments
Renal Impairment
Severe chronic renal impairment (GFR <25 mL/min/1.73 m²):
- Avoid doses >1 g twice daily in kidney transplant recipients beyond immediate post-transplant period 2
- No adjustment needed for delayed graft function immediately post-transplant 2
- Important caveat: Total MPA concentrations may be misleading in severe renal impairment due to altered protein binding—free MPA levels remain relatively stable despite lower total levels 6, 7
The evidence shows that renal dysfunction increases MPAG (inactive metabolite) accumulation and free MPA fraction, but apparent clearance increases, reducing total MPA AUC 8, 6. However, free (active) MPA exposure may not change significantly 6, 7, making dose reductions based solely on total drug levels potentially inappropriate.
Neutropenia
If ANC <1.3 × 10³/µL:
Gastrointestinal Intolerance
For diarrhea or GI adverse effects:
- Interrupt therapy or reduce dose 9
- Consider checking mycophenolate blood levels—high levels suggest drug-induced diarrhea 9
Administration Guidelines
- Timing: Administer on empty stomach for optimal absorption 2
- Exception: In stable renal transplant patients, may give with food if necessary (reduces Cmax by 40% but not AUC) 2
- Missed dose: Take as soon as remembered unless near next scheduled dose 2
Drug Interactions Requiring Dose Modification
Concomitant cyclosporine:
- Reduces MPA exposure by 30-40% compared to tacrolimus or sirolimus due to inhibition of enterohepatic recirculation 10, 11, 7
- May require higher doses or therapeutic drug monitoring 10
Avoid concurrent use with:
- Azathioprine (additive purine metabolism inhibition) 9
Drugs reducing absorption:
- Antacids with magnesium/aluminum, proton pump inhibitors, iron, cholestyramine—separate administration 1
Monitoring Requirements
Laboratory Monitoring Schedule
Initial phase (first month):
- CBC with differential: Weekly for first month 9
- CMP: Weekly for first month 9
- Critical period: First 2-3 weeks after starting or dose increase for azathioprine-related toxicity 12
Months 2-3:
- CBC and CMP: Twice monthly 9
Months 4-12:
- CBC and CMP: Monthly 9
Stable maintenance:
For autoimmune conditions:
- CBC and CMP at baseline, 2-3 weeks after starting/dose changes, then every 3 months on stable dose 3
Therapeutic Drug Monitoring
Target MPA AUC₀₋₁₂:
- 30-60 mg·h/L for transplant recipients 7, 13
- AUC monitoring superior to fixed dosing for clinical outcomes 13
When to check levels:
- Signs/symptoms of GI intolerance (especially diarrhea) 9
- Suspected rejection or inadequate immunosuppression 13
- Significant changes in renal function 7
- Drug interaction concerns 7
Practical monitoring:
- Limited sampling strategies and Bayesian forecasting can estimate AUC without full 12-hour profiling 7, 13
- Trough levels (C₀) alone are inadequate predictors of exposure 7
Special Populations
Pregnancy
- FDA Category D with black box warning 3, 1
- Severe cranial, facial, and cardiac abnormalities reported 5
- Switch to azathioprine ≥3 months before conception if pregnancy contemplated 4
Hepatic Impairment
- No dose adjustment for severe hepatic parenchymal disease in renal transplant patients 2
- Insufficient data for other etiologies 2
Elderly
- Standard doses appropriate 2
- Monitor closely for increased susceptibility to adverse effects
Common Pitfalls to Avoid
Don't rely solely on total MPA levels in renal impairment—free drug concentrations provide better assessment of actual exposure 6, 7
Don't assume bioequivalence with cyclosporine vs. tacrolimus—cyclosporine significantly reduces MPA exposure, potentially requiring dose adjustment 10, 11, 7
Don't overlook the 6-12 hour secondary peak—enterohepatic recirculation contributes ~40% of total AUC 7
Don't continue full doses with severe neutropenia—interrupt or reduce immediately when ANC <1.3 × 10³/µL 2
Don't ignore GI symptoms—diarrhea may indicate excessive drug levels requiring dose reduction 9
Don't use with azathioprine—additive bone marrow suppression risk 9
Don't forget annual dermatologic screening—increased skin malignancy risk with long-term use 3